drugset / Trial / NCT00703937
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.
Timeline
- Start
- 2008-07
- Primary completion
- 2009-07
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferric carboxymaltose | Other / unclassified | 750 mg | Intravenous |